Key Drivers
- Revenue scale
- Positive EBITDA
- High intangibles
AIAI Summary
Omnicell's key investment pivot is that it's becoming a recurring‑revenue software-and-automation platform—evidence of traction exists, but the stock only merits a premium if ARR acceleration, product‑gross‑margin recovery, and sequential bookings improvement materialize in the next few quarters; absent that proof, valuation and limited cash leave little room for execution misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Revenue scale
- •Positive EBITDA
- •High intangibles
Omnicell delivers solid revenue scale, healthy gross margins and positive EBITDA/FCF but is essentially net‑breakeven with large intangibles/deferred revenue and stretched valuation leaving little margin of safety.
Price Behavior
Key Price Behavior Insights:
- •Sustained selling
- •Lower highs
- •Support testing
Stock is in a clear downtrend over the last month, sliding ~18% from about $40.26 to $33.09 with lower highs and lower lows and a failed rebound capped by a $40–$42 supply zone.
~18% decline from ~$40.26 to ~$33.09 over the last month indicating accelerated downside momentum
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •Consensus Moderate Buy
- •Dissenting sell
Omnicell shows growing investor interest as Hillsdale increased its stake and eight brokers hold a consensus "Moderate Buy" (5 buys, 2 holds, 1 sell), signaling moderate analyst conviction as of late Feb 2026.
This combination should bolster near-term sentiment but mixed analyst views may cap upside until clearer operational or earnings catalysts emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings